Meliodays Medical

Executive Summary

Meliodays Medical is a German women's health company developing MelioOne®, a first-in-class intrauterine device (IUD) designed to relieve primary dysmenorrhea (period pain) through a combination of a medical device and locally delivered pharmacological agent. This hormone-free approach offers long-term pain management, addressing a large unmet need in women's health where current options are limited to systemic hormones or analgesics. Founded in 2020 and headquartered in Munich, the company is currently in the pre-clinical stage, focusing on device optimization and initial safety studies. With a novel mechanism that avoids hormone-related side effects, MelioOne® could disrupt the IUD market traditionally dominated by hormonal and copper devices. Success in early studies could position the company for significant clinical and commercial upside, though the pre-clinical stage carries inherent risks.

Upcoming Catalysts (preview)

• Q4 2026Completion of pre-clinical safety & efficacy studies60% success
• Q2 2027Series A funding round to support first-in-human trials50% success
• Q3 2027Regulatory filing (CE Mark or IDE) for clinical trial initiation40% success